• Rudolf Likar, Markus Köstenberger, and Gerhard Nahler.
• Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt am Wörthersee, Österreich.
• Schmerz. 2020 Apr 1; 34 (2): 117-122.

BackgroundCannabis was used for cancer patients as early as about 2500 years ago. Experimental studies demonstrated tumor-inhibiting activities of various cannabinoids more than 40 years ago. In view of the status of tetrahydrocannabinol (THC) as a regulated substance, non-psychotomimetic cannabidiol (CBD) is of particular importance.ObjectivesEfficacy of pure CBD in various animal models as well as initial results (case reports) from patients.MethodsReview of the literature on animal experiments and observations in humans.ResultsPreclinical studies, particularly recent ones, including numerous animal models of tumors, unanimously suggest the therapeutic efficacy of CBD. In isolated combination studies, synergistic effects were generally observed. In addition, CBD may potentially play a role in the palliative care of patients, especially concerning symptoms such as pain, insomnia, anxiety, and depression. Further human studies are warranted.

14 keywords...

hide…